[go: up one dir, main page]

WO2013085338A3 - Pharmaceutical composition for preventing and treating metabolic diseases, comprising nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract as active ingredients - Google Patents

Pharmaceutical composition for preventing and treating metabolic diseases, comprising nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract as active ingredients Download PDF

Info

Publication number
WO2013085338A3
WO2013085338A3 PCT/KR2012/010625 KR2012010625W WO2013085338A3 WO 2013085338 A3 WO2013085338 A3 WO 2013085338A3 KR 2012010625 W KR2012010625 W KR 2012010625W WO 2013085338 A3 WO2013085338 A3 WO 2013085338A3
Authority
WO
WIPO (PCT)
Prior art keywords
root extract
nymphaea tetragona
fractions
metabolic diseases
polyphenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/010625
Other languages
French (fr)
Korean (ko)
Other versions
WO2013085338A2 (en
Inventor
이현선
김문옥
서지희
안종석
이철호
박정준
한아름
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority claimed from KR1020120141752A external-priority patent/KR101462463B1/en
Publication of WO2013085338A2 publication Critical patent/WO2013085338A2/en
Publication of WO2013085338A3 publication Critical patent/WO2013085338A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition for preventing and treating metabolic diseases, comprising nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract. The nymphaea tetragona root extract and fractions thereof effectively inhibit the activity of glycerol-3-phosphate (GPAT), which may cause metabolic diseases, and exhibit inhibitory activity against the biosynthesis of neutral fats in cells and increased insulin-dependent glucose uptake activity in skeletal muscle cells. Thus, nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract can be effectively used in the prevention and treatment of metabolic diseases such as obesity, type 2 diabetes, dyslipidemia, insulin resistance, hepatic steatosis, and non-alcoholic fatty liver disease.
PCT/KR2012/010625 2011-12-07 2012-12-07 Pharmaceutical composition for preventing and treating metabolic diseases, comprising nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract as active ingredients Ceased WO2013085338A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0130165 2011-12-07
KR20110130165 2011-12-07
KR1020120141752A KR101462463B1 (en) 2011-12-07 2012-12-07 Pharmaceutical composition containing Nymphaea tetragona extract, fractions thereof or isolated polyphenolic compounds for prevention or treatment of metabolic disease
KR10-2012-0141752 2012-12-07

Publications (2)

Publication Number Publication Date
WO2013085338A2 WO2013085338A2 (en) 2013-06-13
WO2013085338A3 true WO2013085338A3 (en) 2013-08-08

Family

ID=48575025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/010625 Ceased WO2013085338A2 (en) 2011-12-07 2012-12-07 Pharmaceutical composition for preventing and treating metabolic diseases, comprising nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract as active ingredients

Country Status (1)

Country Link
WO (1) WO2013085338A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555287A (en) * 2013-06-19 2016-05-04 捷通国际有限公司 Plant-based ketohexokinase inhibitors for weight management support
CN110680825A (en) * 2018-07-06 2020-01-14 大江生医股份有限公司 Mango young fruit extract and application of compound thereof in preparing pharmaceutical composition for reducing fat accumulation or oxidative damage of liver cells
CN109694394B (en) * 2018-12-07 2022-08-09 兰州大学 Preparation method and application of tannin extract in sea buckthorn
CN112057374B (en) * 2019-06-10 2023-11-21 大江生医股份有限公司 Mango fruit extract for skin care and health care

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006335725A (en) * 2005-06-03 2006-12-14 Taiyo Kagaku Co Ltd Composition for improving bloodstream
US20100063153A1 (en) * 2006-12-22 2010-03-11 The Johns Hopkins University Anti-cholesterolemic compounds and methods of use
KR20100124359A (en) * 2009-05-19 2010-11-29 제주대학교 산학협력단 The radiation raioprotective composition included the geraniin isolated nymphaea tetragona extraction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006335725A (en) * 2005-06-03 2006-12-14 Taiyo Kagaku Co Ltd Composition for improving bloodstream
US20100063153A1 (en) * 2006-12-22 2010-03-11 The Johns Hopkins University Anti-cholesterolemic compounds and methods of use
KR20100124359A (en) * 2009-05-19 2010-11-29 제주대학교 산학협력단 The radiation raioprotective composition included the geraniin isolated nymphaea tetragona extraction

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BING, SO JIN ET AL.: "1,2,3,4,6-Penta-O-galloyl-beta-D-glucose Pretects Splenocytes against Radiation-Induced Apoptosis in Murine Splenocytes", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 33, no. 7, 2010, pages 1122 - 1127 *
CHA, MI RAN ET AL.: "a-glucosidase Inhibitors from the Branches Extract ofCotinus coggygria", KOREAN JOURNAL OF PHARMACOGNOSY, vol. 40, no. 3, 2009, pages 229 - 232, XP053014138 *
PALANISAMY, UMA D. ET AL.: "Rapid isolation of geraniin from Nephelium lappaceum rind waste and its anti-hyperglycemic activity", FOOD CHEMISTRY, vol. 127, 21 December 2010 (2010-12-21), pages 21 - 27 *
PARK, JONG KOO ET AL.: "Hypocholestrolemic Effect of CJ90002 in Hamsters: A Potent Inhibitor for Squalene Synthase from Paeonia moutan", JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, vol. 12, no. 2, 2002, pages 222 - 227 *

Also Published As

Publication number Publication date
WO2013085338A2 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
Margină et al. Natural products—friends or foes?
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2009103884A3 (en) Composition for human and/or animal nutrition, uses thereof and yeasts
WO2012165914A3 (en) Novel diphenylmethane derivatives as sglt2 inhibitors
WO2012108689A3 (en) Novel compound having skin-whitening, anti-oxidizing and ppar activities and medical use therefor
WO2009153496A3 (en) Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia
WO2011159067A3 (en) Thiazole derivatives as sglt2 inhibitors and pharmaceutical composition comprising same
HK1216506A1 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
WO2011090270A3 (en) Composition containing osmotin for preventing and treating neurological disorders
WO2009090237A3 (en) Fungicide hydroximoyl-tetrazole derivatives
WO2009048249A3 (en) Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same
WO2012157978A3 (en) Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis
WO2012040804A3 (en) Synergistic combinations of triazoles, strobilurins and benzimidazoles, uses, formulations, production processes and applications using the same
WO2012108677A3 (en) Novel compound having skin-whitening, anti-oxidizing and ppar activities and medical use therefor
WO2013085338A3 (en) Pharmaceutical composition for preventing and treating metabolic diseases, comprising nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract as active ingredients
WO2011159129A3 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
WO2011080254A3 (en) Fungicide hydroximoyl-heterocycles derivatives
WO2012033390A3 (en) Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
WO2012099271A3 (en) Herbicidal composition
WO2013025073A3 (en) Composition for preventing or treating diabetes complications containing quamoclit pennata extract
WO2012064159A3 (en) Anticancer composition
WO2016190566A3 (en) Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient
WO2011065791A3 (en) Metabolism accelerating composition comprising astragali radix extract
WO2009022842A3 (en) Pharmaceutical composition for preventing and treating cell proliferative disease comprising mixture of feather of birds and scale of fish as an active ingredient
WO2010109198A3 (en) Compositions to combat ectoparasites

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12856180

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12856180

Country of ref document: EP

Kind code of ref document: A2